ECSP10010105A - Antagonistas de cgrp - Google Patents

Antagonistas de cgrp

Info

Publication number
ECSP10010105A
ECSP10010105A EC2010010105A ECSP10010105A ECSP10010105A EC SP10010105 A ECSP10010105 A EC SP10010105A EC 2010010105 A EC2010010105 A EC 2010010105A EC SP10010105 A ECSP10010105 A EC SP10010105A EC SP10010105 A ECSP10010105 A EC SP10010105A
Authority
EC
Ecuador
Prior art keywords
salts
cgrp antagonists
hydrates
diastereoisomers
tautomers
Prior art date
Application number
EC2010010105A
Other languages
English (en)
Inventor
Dirk Stenkamp
Klaus Rudolf
Henri Doods
Stephan Georg Mueller
Gerhard Schaenzle
Georg Dahmann
Dirk Gottschling
Annekatrin Heimann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP10010105A publication Critical patent/ECSP10010105A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Son objeto de la presente invención nuevos antagonistas de CGRP de la fórmula general (I) , (I)en la que U, V, X, Y, R1, R2 y R3 están definidos como se menciona en lo que sigue, sus tautómeros, sus isómeros, sus diastereoisómeros, sus enantiómeros, sus hidratos, sus mezclas y sus sales, así como los hidratos de las sales, en especial sus sales fisiológicamente compatibles con ácidos o bases inorgánicos u orgánicos, medicamentos que contienen a estos compuestos, su uso y procedimientos para su preparación.
EC2010010105A 2007-10-18 2010-04-14 Antagonistas de cgrp ECSP10010105A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07118811 2007-10-18

Publications (1)

Publication Number Publication Date
ECSP10010105A true ECSP10010105A (es) 2010-06-29

Family

ID=39047647

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010105A ECSP10010105A (es) 2007-10-18 2010-04-14 Antagonistas de cgrp

Country Status (17)

Country Link
US (1) US8450327B2 (es)
EP (2) EP2205599B1 (es)
JP (1) JP5366960B2 (es)
KR (1) KR20100091972A (es)
CN (1) CN101827845A (es)
AU (1) AU2008313733A1 (es)
BR (1) BRPI0817835A2 (es)
CA (1) CA2702503A1 (es)
CO (1) CO6270226A2 (es)
EA (1) EA201000612A1 (es)
EC (1) ECSP10010105A (es)
IL (1) IL204928A0 (es)
MA (1) MA31782B1 (es)
MX (1) MX2010003849A (es)
NZ (1) NZ585347A (es)
TN (1) TN2010000173A1 (es)
WO (1) WO2009050234A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065381A1 (de) * 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
KR20100091972A (ko) 2007-10-18 2010-08-19 베링거 인겔하임 인터내셔날 게엠베하 Ｃｇｒｐ 길항제
US8829006B2 (en) * 2007-11-22 2014-09-09 Boehringer Ingelheim International Gmbh Compounds
CN102791692B (zh) * 2010-03-12 2015-05-27 日本曹达株式会社 叔丁氧基羰基胺化合物的制造方法
RU2019123406A (ru) 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
MX388576B (es) 2016-06-07 2025-03-20 Jacobio Pharmaceuticals Co Ltd Derivados heterociclicos novedosos utiles como inhibidores de shp2.
EA202190196A1 (ru) 2017-03-23 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
EP4408418A1 (en) 2021-09-27 2024-08-07 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010042614A (ko) 1998-04-10 2001-05-25 윌리암스 로저 에이 비트로넥틴 길항제로서 복소환식 글리실 베타-알라닌 유도체
DE19911039A1 (de) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CA2422013A1 (en) 2000-09-14 2002-03-21 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
US6831087B2 (en) 2001-11-09 2004-12-14 Hoffmann-La Roche Inc. Pyridine substituted isoquinoline derivatives
RS52552B (sr) 2002-06-05 2013-04-30 Bristol-Myers Squibb Company Antagonisti, peptidnog receptora koji je u vezi sa kalcitoninskim genom
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1697342A2 (en) 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DE102004018795A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018794A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7659300B2 (en) 2004-09-08 2010-02-09 Merck Sharp & Dohme Corp. Monocyclic anilide spirolactam CGRP receptor antagonists
EP1794133B1 (en) * 2004-09-09 2011-12-14 Merck Sharp & Dohme Corp. Aryl spirolactam cgrp receptor antagonists
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1891018B1 (en) 2005-05-24 2011-11-16 Vertex Pharmaceuticals, Inc. Modulators of atp-binding cassette transporters
BRPI0613958A2 (pt) 2005-06-29 2011-02-22 Palau Pharma Sa composto bicìclico, seu uso como inibidor p38 e composição farmacêutica contendo o mesmo
DE102005050892A1 (de) 2005-10-21 2007-04-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
AU2007284994B2 (en) 2006-05-09 2010-04-22 Merck Sharp & Dohme Corp. Substituted spirocyclic CGRP receptor antagonists
WO2008070014A2 (en) 2006-12-04 2008-06-12 Neurogen Corporation Biaryl ketone-substituted piperidines
WO2009034029A2 (de) 2007-09-07 2009-03-19 Boehringer Ingelheim International Gmbh 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
KR20100091972A (ko) 2007-10-18 2010-08-19 베링거 인겔하임 인터내셔날 게엠베하 Ｃｇｒｐ 길항제
EP2062889A1 (de) * 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
US8829006B2 (en) * 2007-11-22 2014-09-09 Boehringer Ingelheim International Gmbh Compounds
WO2009065922A2 (de) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Organische verbindungen

Also Published As

Publication number Publication date
EP2205599A1 (de) 2010-07-14
MA31782B1 (fr) 2010-10-01
JP5366960B2 (ja) 2013-12-11
US8450327B2 (en) 2013-05-28
MX2010003849A (es) 2010-04-27
AU2008313733A1 (en) 2009-04-23
IL204928A0 (en) 2010-11-30
KR20100091972A (ko) 2010-08-19
CN101827845A (zh) 2010-09-08
EA201000612A1 (ru) 2010-10-29
EP2386558A1 (de) 2011-11-16
US20110172218A1 (en) 2011-07-14
EP2205599B1 (de) 2012-06-06
NZ585347A (en) 2011-09-30
JP2011500637A (ja) 2011-01-06
CA2702503A1 (en) 2009-04-23
BRPI0817835A2 (pt) 2015-03-31
CO6270226A2 (es) 2011-04-20
WO2009050234A1 (de) 2009-04-23
EP2386558B1 (de) 2014-10-01
TN2010000173A1 (fr) 2011-11-11

Similar Documents

Publication Publication Date Title
ECSP10010105A (es) Antagonistas de cgrp
UY29437A1 (es) Nuevos antagonistas de cgrp
UY28859A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
UY28040A1 (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos.
UY30314A1 (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
CU23834B1 (es) Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9
ECSP088194A (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, así como su uso como medicamentos
ECSP088638A (es) Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados
ECSP12012161A (es) Compuestos en calidad de antagonistas de Bradiquinina-b1
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
UY29176A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen, métodos para su preparación y sus usos.
UY27722A1 (es) Nuevas piperidinas sustituidas, medicamentos que contienen estos compuestos y procedimientos para su preparación.
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
ECSP10010722A (es) Compuestos orgánicos
UY30979A1 (es) Pirrolidinamidas sustituidas, su preparacion y su uso como medicamentos
UY28848A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, y su empleo como medicamentos
DOP2011000176A (es) Compuestos organicos
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
CO6331335A2 (es) Nuevos compuestos antagonistas de los receptores b1 de bradiquinina
UY29267A1 (es) Derivados de piperidina y su uso como agentes antiinflamatorios
CO6150138A2 (es) Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc
UY31774A (es) Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos
CR9786A (es) Compuestos de bencimidazol-tiofeno
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
ECSP078058A (es) Nuevas glicinamidas sustituidas, su preparación y su uso como medicamentos